Because of its long duration of action, bupivacaine (BUP) is frequently the local anesthetic (LA) chosen for continuous epidural and other regional analgesia techniques. However, lethal arrhythmias, including cardiac arrest, can occur after an accidental intravascular BUP injection (1). Profound myocardial depression is another common feature of acute BUP intoxication (2,3). Resuscitation from BUP-induced cardiovascular collapse has been difficult and often unsuccessful (1,4). Accordingly, the new long-acting LAs, ropivacaine (ROP) and levobupivacaine (LBUP), have been developed as safer alternatives to BUP when large volumes and large concentrations are used to establish upper and lower extremity nerve blocks for surgical anesthesia, and during continuous infusions for pain management.
LBUP and ROP are S(−) enantiomers of two different molecules, l-butyl-2′,6′-pipecoloxylidide and l-propyl-2′,6′-pipecoloxylidide, respectively. Only LBUP is the S(−) enantiomer of BUP. Both molecules possess physicochemical and LA properties similar to racemic BUP. These single enantiomeric preparations were developed based on the observation that S(−) isomers possess equal anesthetic potency to the R(+) isomers, but appear less cardiotoxic than the R(+) isomers (5). Animal studies demonstrate that ROP depresses cardiac electrophysiology and function less than BUP (6,7). LBUP produces fewer and less deleterious arrhythmias than equivalent concentrations of BUP (8). The lower affinity of the S(−) isomer for the inactivated state of the cardiac sodium channel (9) and for the cardiac potassium channel (10) than the R(+) isomer may explain some of these stereoselective differences in cardiotoxicity.
Clinical and laboratory accounts of acute intoxication from intravascular injections of ROP and, more recently, one LBUP report, suggest favorable outcomes (11–15). There is scant literature about cardiovascular toxicity that might occur from systemic absorption and drug accumulation during long-term epidural or regional infusions. Moreover, the clinically relevant questions as to whether the newer LAs provide a greater margin of safety, or are less frequently associated with unsuccessful resuscitation than BUP, have not been answered.
We compared the success of resuscitation after incremental infusions of ROP, LBUP, BUP, and lidocaine (LIDO) to the point of cardiovascular collapse in dogs. The LAs were infused at rates chosen to simulate the plasma concentrations that might be achieved from cumulative effects of systemic absorption during various regional anesthetic techniques (16,17) and the levels that might be expected from an accidental intravascular injection (11,14). To eliminate the confounding effects of seizures and their metabolic consequences, including hypoxia, hypercarbia, and acidosis, the animals were anesthetized and ventilated for the study. Comparisons of the arrhythmogenic effects of these drugs have been shown in a companion report (18).
Our investigation was reviewed and approved by our animal care and use committee. All experimental procedures and protocols complied with the Guiding Principles in the Care and Use of Animals, approved by the Council of the American Physiological Society.
Forty heartworm-free, nonpregnant, purebred hounds (Harlan Sprague Dawley, Inc., Indianapolis, IN), weighing between 18 and 21 kg, were used. Anesthesia was induced with 20 mg/kg of IV thiopental and maintained with a continuous infusion of fentanyl (0.3 μg · kg−1 · min−1) and midazolam (0.005 μg · kg−1 · min−1). The dogs were tracheally intubated and ventilated to normocapnic values before starting the experiment with oxygen-enriched room air using a volume-cycled ventilator. Both femoral arteries and veins were cannulated for arterial pressure monitoring and sampling, and for drug and fluid infusion, respectively. An 8.5F introducer catheter was inserted into the left external jugular vein for the administration of resuscitation drugs. Body temperature was measured rectally and maintained at 37° to 38°C during the experiment by using a heating blanket. A continuous infusion of 0.9% NaCl at 3 mL · kg−1 · h−1 was given throughout the experiment. The urinary bladder was catheterized. A left thoracotomy and pericardotomy were performed for placement of left-ventricular pacing wires and to allow open-chest heart massage and direct cardiac countershock. Dogs were assigned randomly to receive incremental infusions of vehicle (saline;n = 3) or one of four LAs until cardiovascular collapse: BUP (n = 10), LBUP (n = 10), ROP (n = 10), LIDO (n = 7). The principal investigator, who gathered the data, remained blinded to the LA until all experiments had been completed. The dosing regimens for BUP, LBUP, and ROP were based on drug clearance rates in dogs provided by AstraZeneca Research and Development (Södertälje, Sweden) and the target plasma concentrations were 2, 4, 8, 16, and 19 mg/L. A clearance rate of 0.9 L · h−1 · kg−1 was assumed for BUP and LBUP and a clearance rate of 1.16 L · h−1 · kg−1 was assumed for ROP. The clearance rate assumed for LIDO was 1.71 L · h−1 · kg−1, and the target plasma concentrations to be achieved were 8, 16, 32, and 64 mg/L, assuming a BUP-to-LIDO potency ratio of 4:1. Drug infusions consisted of a 12-min initial infusion (defined as 3 times the calculated steady-state rate) followed by a 12-min maintenance infusion (defined as: clearance rate (L · h−1 · kg−1) × desired target concentration [mg/L] = mg · h−1 · kg−1). From previous pharmacokinetic data (AstraZeneca R&D, Södertälje, Sweden), we assumed that 88% of the desired plasma concentration would be achieved after the initial 12-min loading infusion, and that 92% of the desired target concentration would be achieved after the steady-state infusion. The infusion protocol for vehicle was set at a rate that corresponded to the rate used for the BUP-treated dogs.
A surface lead II electrocardiogram and femoral arterial blood pressure were continuously monitored on an oscilloscope and recorded on a polygraph interfaced with a computer for data retrieval. Two insulated silver-coated wires were inserted 1 cm apart into the epicardial surface of the left ventricle to allow for pacing. Standard, programmable electrical stimulation (PES) protocols were also used, as described previously (18), to determine the arrhythmogenic potential of each LA.
Arterial blood samples were collected in heparinized syringes for blood gas analysis at baseline and at the end of each maintenance infusion until cardiovascular collapse. Minute ventilation was adjusted or a sodium bicarbonate solution (8.4%) was administered to maintain arterial blood chemistry within the following ranges: pHa 7.35 to 7.45; Paco2 30 to 40 mm Hg; and Pao2 150 to 300 mm Hg. Ten milliliters of arterial blood was collected for determination of free and total LA concentrations at baseline, cardiovascular collapse, and after 20 min of successful resuscitative maneuvers. The samples were stored on ice until they were centrifuged to obtain plasma. Plasma samples were stored at −20°C pending batch gas chromatographic analysis by AstraZeneca’s reference laboratory.
Cardiovascular collapse was defined as asystole, sustained ventricular tachycardia (spontaneous or PES-induced), ventricular fibrillation, or a mean blood pressure ≤45 mm Hg persisting for 15 consecutive s. Resuscitative procedures consisted of the following:
1. Hypotension was treated with IV epinephrine (EPI) (0.75 mg), which was repeated several times if necessary until a mean blood pressure ≥55 mm Hg was achieved. If hypotension was accompanied with bradycardia (≤50 beats/min, ventricular pacing at a rate of 120–130 bpm was initiated.
2. Asystole was treated with ventricular pacing at a rate of 120–130 bpm. If this was not effective, IV EPI (0.75 mg) and atropine (0.4 mg) were given.
3. Sustained ventricular tachycardia, without hypotension, was treated with overdrive ventricular pacing. If this was not effective, IV bretylium (5–10 mg/kg) was administered over 1 min. LIDO has been the first line antiarrhythmic for ventricular tachycardia (and ventricular fibrillation) treatment according to the advanced cardiac life support guidelines (19); however, we bypassed this drug because of the experimental conflict that it imposed.
4. Ventricular fibrillation and sustained ventricular tachycardia with hypotension were treated with the following sequence of maneuvers: direct cardiac massage, three consecutive direct current countershocks of 15 to 30 W-s using internal paddles, IV EPI (0.75 mg), additional shocks, and IV bretylium (5–10 mg/kg over 1–2 min). Cardiac massage was administered to aid in the circulation of resuscitative drugs. This sequence of maneuvers was repeated for 20 min until return of stable rhythm and blood pressure (mean arterial pressure [MAP] ≥55 mm Hg).
Outcomes after 20 min of resuscitation were defined as: successful (stable rhythm and MAP ≥55 after 20 min without need for continued drug therapy), successful with continued need for pharmacologic support (stable rhythm and MAP ≤55 after 20 min unless additional EPI was given), or death. The animals were euthanized with IV KCl, 100 mEq, after 20 min had elapsed.
BUP HCl and ROP HCl were commercially available 0.5% preservative-free solutions and LIDO HCl was a commercially available 2.0% preservative-free solution provided by AstraZeneca (Philadelphia, PA). LBUP was provided by AstraZeneca (Södertälje, Sweden) in dry form. Before its use, it was reconstituted in normal saline with pH adjustment to provide a 0.5% solution. EPI (American Regent, Inc., Shirley, NY) and atropine (American Regent Inc.) solutions were prepared from commercially available multiple-dose vials. Sodium bicarbonate and bretylium (Abbott, North Chicago, IL) were from single-dose commercially available ampules.
Data were analyzed by using SAS Version 6.1 (SAS Institute, Cary, NC). Analysis of variance was used to analyze hemodynamic measurements and plasma concentration data. Log transformation was used when this maneuver improved the “normality” of distributions. Post hoc tests were corrected for multiple comparisons when the overall effects or interactions were not significant (Fisher Protected LSD). Exact χ2 was used to test for differences among groups with respect to the ability to resuscitate. Values of P ≤ 0.05 were considered significant.
All dogs were studied at equivalent times after the administration of anesthesia and instrumentation (90 ± 20 min). Dogs were similar in weight, and had similar MAP, heart rates, and acid-base status at baseline before the administration of the LAs (Table 1). None of the control animals (n = 3) died during our experiments.
The effect of incremental increases in plasma concentrations of LAs on heart rate and mean blood pressure was similar with BUP, LBUP, ROP, and LIDO. The heart rate, MAP, and LA plasma concentrations relative to the time course of the experimental protocol are shown in Figures 1 and 2. Cardiovascular collapse was identified by hypotension in the majority of animals. There was no difference among groups in the incidence of spontaneous or PES-induced lethal arrhythmias precipitating resuscitation, as previously described (18).
Resuscitation outcomes for each group are depicted in Figure 3. There were significant differences between LIDO and BUP, and between LIDO and ROP with regard to success, success with continued therapy, and death (P < 0.05). Continued therapy was required in 86% of dogs receiving LIDO compared with only 10%–30% of dogs receiving the other drugs (P < 0.002). Mortality from BUP, LBUP, ROP, and LIDO was 50%, 30%, 10%, and 0%, respectively (P = 0.065). Differences in mortality were significant only between BUP- and LIDO-treated animals (P = 0.04). There was no significant difference between BUP versus ROP dogs (P = 0.14) or BUP versus LBUP dogs (P = 0.65) with respect to inability to resuscitate (death). In every case (n = 9), animals that were unable to be resuscitated died of refractory ventricular fibrillation.
EPI was required for resuscitation in 9 of 10 BUP dogs, 10 of 10 LBUP dogs, 8 of 10 ROP dogs, and 6 of 7 LIDO dogs. There was an overall treatment effect with respect to the number of animals that developed EPI-induced ventricular fibrillation: 4 of 9 BUP dogs, 2of 10 LBUP dogs, 0 of 8 ROP dogs, and 0 of 6 LIDO dogs (P < 0.05). However, when doing pair-wise comparisons, there was not enough power to determine which were statistically significant.
The median cumulative doses (mg/kg) and median LA plasma concentrations required to produce cardiac collapse are shown in Table 2. Pair-wise contrasts comparing cardiac collapse concentration ratios and their 95% confidence limits found LIDO to differ significantly from the other three LAs (P < 0.005). The unbound plasma concentrations at collapse for ROP-treated dogs were significantly larger than for BUP-treated animals (P < 0.01). In all groups, plasma concentrations of LA 20 min after a successful resuscitation were dramatically decreased from the concentrations that resulted in collapse.
Our study indicates that LA cardiac toxicity may differ among the amide LAs for both pharmacodynamic and pharmacokinetic reasons. LIDO overdosage resulted in profound hypotension and myocardial depression that required continued EPI therapy, whereas the longer-acting, more lipid-soluble drugs, BUP, LBUP, and ROP, produced toxicity from which resuscitation was sometimes not successful, but in other instances was successful without the need for continued therapy. Additionally, EPI-induced ventricular fibrillation tended to occur more often in BUP dogs than in ROP or LIDO dogs. Finally, the unbound plasma concentrations of ROP associated with cardiovascular collapse were significantly larger than those levels required for BUP toxicity. The concentrations of BUP and LBUP at the time of cardiovascular collapse were similar.
The cause of cardiovascular collapse for both the long-acting (e.g., BUP) and the short-acting (e.g., LIDO) amide LAs was typically hypotension from myocardial depression rather than from arrhythmias (18). Although others have reported an increased incidence of arrhythmias with BUP than with LIDO intoxication (6,20), these studies were conducted in conscious, spontaneously ventilating animals in which seizures preceded the cardiac effects, resulting in a hyperdynamic circulation preceding circulatory collapse (4). Such confounding factors associated with seizure activity, including hypoxia, hypercarbia, acidemia, and hyperkalemia (21,22), were eliminated by use of our normoventilated, anesthetized canine model.
Our findings are consistent with the work of Liu et al. (2) in anesthetized dogs, in which “pump failure” was the cause of death in both BUP- and LIDO-treated dogs. In fact, the hypotension that resulted was often more severe with LIDO than BUP overdosage. In our study, 86% of LIDO-treated dogs required continued EPI dosing during resuscitation because of continuing hypotension whereas continued EPI dosing was required in only 10%–30% of the dogs given BUP, LBUP, and ROP. One explanation for this increased need for vasoactive support after LIDO may be that the absence of lethal arrhythmias (18) permits a relatively larger amount of LIDO (compared with the other drugs) to be infused, approaching that required for contractile failure. Interestingly, concentrations of LIDO necessary to produce depression of cardiac contractility have been 10 times larger than BUP in in vitro studies (23,24). Nevertheless, similar to the findings of Chadwick (25), all of the LIDO animals survived whereas only half of the BUP-intoxicated animals survived, despite the increased need for continued vasoactive support after LIDO.
The S(−) ROP enantiomer appears to be potentially less cardiotoxic than either its S(−) butyl homologue LBUP or racemic BUP. Unsuccessful resuscitation, or death, occurred in only 10% of the ROP-treated dogs as compared with 50% and 30% of BUP- and LBUP-treated dogs, respectively. A power analysis using the observed mortality rates indicates that 30 dogs per group would have been required to detect significant differences between BUP and ROP, and 140 dogs per group would have been required to detect differences between BUP and LBUP (power >0.8, α = 0.05). ROP was also associated with fewer deaths and a decreased incidence of electrocardiographic QRS prolongation, ventricular arrhythmias, and ventricular tachycardia than LBUP or BUP in conscious rats (26). Consistent with our findings, Huang et al. (8) reported a decreased cardiotoxicity with IV LBUP than with BUP in conscious sheep. However, Kasten and Martin (27) found that sheep were more sensitive than dogs to cardiotoxic doses of BUP. Nevertheless, our study is the first to compare the systemic toxicity and the success of resuscitation of all three long-acting amide LAs after incremental overdosage to the point of cardiovascular collapse in the intact animal.
The pharmacokinetic profiles of the BUP enantiomers and ROP appear to be different. The unbound plasma concentrations at the time of collapse were larger for ROP compared with BUP, whereas the cumulative dose and unbound plasma concentrations of LBUP and BUP were similar. In conscious sheep, however, the differences between the unbound drug concentrations of ROP 7.44 ± 1.64 μg/mL, compared with BUP 3.44 ± 1.78 μg/mL, were similar to the differences observed between LBUP 6.82 ± 2.45 μg/mL and BUP after a constant rate IV infusion until circulatory collapse (28). Similarly, Morrison et al. (29) recently reported that LBUP was less toxic than BUP, but not different from ROP in anesthetized swine receiving intracoronary bolus injections of LA until death. In contrast, Feldman et al. (13) found no significant difference in peak plasma concentrations between ROP (5.75 ± 0.23 μg/mL) and BUP (5.04 ± 0.13 μg/mL) after rapid IV injection to the point of collapse in conscious dogs. Inconsistencies in these results may be attributable to species differences (27) and/or differences in racemate kinetics after prolonged versus short (bolus) infusions (30).
We observed an increased incidence of EPI-induced ventricular fibrillation in the BUP-intoxicated dogs than in dogs given LIDO or ROP. EPI was chosen for treatment of hypotension from LA-induced myocardial depression because of its inotropic, chronotropic, and vasopressor properties, and because it is routinely used for cardiac arrest (19). Large doses of EPI (≥30 μg/kg) are effective for LA toxicity in dogs (31), cats (25), and rats 1. The use of EPI for LA cardiotoxicity is not, however, without drawbacks. In anesthetized rats, Heavner et al. (32) observed an increased incidence of arrhythmias with EPI and isoproterenol compared with amrinone, dopamine, or norepinephrine for treatment of BUP-induced asystolic arrest. Similarly, EPI-induced ventricular arrhythmias have been reported in dogs (13,33), sheep (22), and pigs (34) treated for BUP-induced circulatory collapse. One explanation for EPI-induced ventricular arrhythmias in the setting of BUP toxicity is the rapid increase in ventricular pressure that occurs, increasing myocardial oxygen demand and predisposing the heart to ventricular ectopy. This mechanism is unlikely, however, in our study because both the LIDO- and ROP-treated animals had rapid, hyperdynamic responses after EPI therapy that were similar to the BUP-intoxicated animals. Alternatively, there could be a differential modulatory effect of β stimulation on the slow inward calcium currents in the heart. BUP exhibits a potency about 5 times greater than LIDO in blocking slow calcium channels (35). EPI increases the frequency and duration of calcium channel opening (36), which can potentiate BUP-induced oscillations in the membrane potential (37), possibly triggering extrasystoles and uncovering reentrant pathways. Finally, LIDO and ROP may inhibit reentrant arrhythmias from EPI. Whether LA stereoselectivity or structure plays a role in this effect is unclear, because EPI-induced ventricular arrhythmias also occurred in dogs intoxicated with LBUP.
In summary, we found that the pattern of LA cardiovascular toxicity and the LA concentration that produces cardiovascular toxicity differs among LAs. There were consistent differences among the LAs, the sum of which suggests that larger doses and blood concentrations of ROP and LIDO will be tolerated as compared with BUP and LBUP. LIDO intoxication results in myocardial depression from which resuscitation is consistently successful but will require continuing drug support. After BUP, LBUP, or ROP, resuscitation is not always successful, and the administration of EPI may lead to severe ventricular arrhythmias. Nevertheless, continuing resuscitative therapy will not usually be required in our model of gradual IV overdosage of these longer-acting amide LAs. Furthermore, larger plasma concentrations of ROP than BUP are present after resuscitation, suggesting a greater margin of safety when larger volumes and concentrations are used to establish upper and lower extremity nerve blocks for surgical anesthesia and during long-term infusions for pain management.
1 Wu SJ, Bircher NG, Safar P. Epinephrine reverses bupivacaine-induced cardiac arrest in rats [abstract]. Anesthesiology 1990;73:A303. Cited Here...
1. Albright GA. Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. Anesthesiology 1979; 51: 285–7.
2. Liu P, Feldman HS, Covino BM,et al. Acute cardiovascular toxicity of intravenous amide local anesthetics in anesthetized ventilated dogs. Anesth Analg 1982; 61: 317–22.
3. Coyle DE, Porembka DT, Sehlhorst CS,et al. Echocardiographic evaluation of bupivacaine cardiotoxicity. Anesth Analg 1994; 79: 335–9.
4. Reiz S, Nath S. Cardiotoxicity of local anaesthetic agents. Br J Anaesth 1986; 58: 736–46.
5. Aberg G. Toxicological and local anaesthetic effects of optically active isomers of two local anaesthetic compounds. Acta Pharmacol Toxicol 1972; 31: 273–86.
6. Feldman HS, Arthur GR, Covino BG. Comparative systemic toxicity of convulsant and supraconvulsant doses of intravenous ropivacaine, bupivacaine, and lidocaine in the conscious dog. Anesth Analg 1989; 69: 794–801.
7. Moller R, Covino BG. Cardiac electrophysiologic properties of bupivacaine and lidocaine compared with those of ropivacaine, a new amide local anesthetic. Anesthesiology 1990; 72: 322–9.
8. Huang YF, Pryor ME, Mather LE, Veering BT. Cardiovascular and central nervous system effects of intravenous levobupivacaine and bupivacaine in sheep. Anesth Analg 1998; 86: 797–804.
9. Valenzuela C, Snyders DJ, Bennett PB,et al. Stereoselective block of cardiac sodium channels by bupivacaine in guinea pig ventricular myocytes. Circulation 1995; 92: 3014–24.
10. Valenzuela C, Delpon E, Tamkun MM, et al. Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. Biophys J 1995;69:418–27.
11. Ruetsch YA, Fattinger KE, Borgeat A. Ropivacaine-induced convulsions and severe cardiac dysrhythmia after sciatic block. Anesthesiology 1999; 90: 1784–6.
12. Scott DB, Lee A, Fagan D,et al. Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg 1989; 69: 563–9.
13. Feldman HS, Arthur GR, Pitkanen M,et al. Treatment of acute systemic toxicity after the rapid intravenous injection of ropivacaine and bupivacaine in the conscious dog. Anesth Analg 1991; 73: 373–84.
14. Ala-Kokko TI, Löppönen A, Alahuhta S. Two instances of central nervous system toxicity in the same patient following repeated ropivacaine-induced brachial plexus block. Acta Anaesthesiol Scand 2000; 44: 623–26.
15. Kopacz DJ, Allen HW. Accidental intravenous levobupivacaine. Anesth Analg 1999; 89: 1027–9.
16. Moore DC, Mather LE, Bridenbaugh PO,et al. Arterial and venous plasma levels of bupivacaine following epidural and intercostal nerve blocks. Anesthesiology 1976; 45: 39–45.
17. Moore DC, Mather LE, Bridenbaugh LD,et al. Arterial and venous plasma levels of bupivacaine following peripheral nerve blocks. Anesth Analg 1976; 55: 763–8.
18. Groban L, Deal DD, Vernon JC,et al. Ventricular arrhythmias with or without programmed electrical stimulation after incremental overdosage with lidocaine, bupivacaine, levobupivacaine, or ropivacaine. Anesth Analg 2000; 91: 1103–11.
19. American Heart Association. Textbook of advanced cardiac life support. Dallas: American Heart Association, 1997.
20. Kotelko DM, Shnider SM, Dailey PA,et al. Bupivacaine-induced cardiac arrhythmias in sheep. Anesthesiology 1984; 60: 10–8.
21. Moore DC, Crawford RD, Scurlock JE. Severe hypoxia and acidosis following local anesthetic-induced convulsions. Anesthesiology 1980; 53: 259–60.
22. Rosen MA, Thigpen JW, Shnider SM,et al. Bupivacaine- induced cardiotoxicity in hypoxic and acidotic sheep. Anesth Analg 1985; 64: 1089–96.
23. Tanz RD, Heskett T, Loehning RW, Fairfax CA. Comparative cardiotoxicity of bupivacaine and lidocaine in the isolated perfused mammalian heart. Anesth Analg 1984; 63: 549–56.
24. Lynch C III. Depression of myocardial contractility in vitro
by bupivacaine, etidocaine, and lidocaine. Anesth Analg 1986; 65: 551–9.
25. Chadwick HS. Toxicity and resuscitation in lidocaine- or bupivacaine-infused cats. Anesthesiology 1985; 63: 385–90.
26. Ericson A-C, Avesson M. Effects of ropivacaine, bupivacaine and S(−)-bupivacaine on the ECG after rapid IV injections to conscious rats. Int Monitor Reg Anesth 1996; 8: 51.
27. Kasten GW, Martin ST. Comparison of resuscitation of sheep and dogs after bupivacaine-induced cardiovascular collapse. Anesth Analg 1986; 65: 1029–32.
28. Santos AC. Systemic toxicity of levobupivacaine, bupivacaine and ropivacaine in nonpregnant and pregnant sheep. Anesth Analg 2000; 90: S297.
29. Morrison SG, Dominguez JJ, Frascarolo P, Reiz S. A comparison of the electrocardiographic cardiotoxic effects of racemic bupivacaine, levobupivacaine, and ropivacaine in anesthetized swine. Anesth Analg 2000; 90: 1308–14.
30. Mazoit JX, Lambert C, Berdeaux A,et al. Pharmacokinetics of bupivacaine after short and prolonged infusions in conscious dogs. Anesth Analg 1988; 67: 961–6.
31. Kasten GW, Martin ST. Successful cardiovascular resuscitation after massive intravenous bupivacaine overdosage in anesthetized dogs. Anesth Analg 1985; 64: 491–7.
32. Heavner JE, Pitkanen MT, Shi B, Rosenberg PH. Resuscitation from bupivacaine-induced asystole in rats: comparison of different cardioactive drugs. Anesth Analg 1995; 80: 1134–9.
33. Igarashi T, Hirabayashi Y, Saitoh K,et al. Dose-related cardiovascular effects of amrinone and epinephrine in reversing bupivacaine-induced cardiovascular depression. Acta Anaesthesiol Scand 1998; 42: 698–706.
34. Bernards CM, Carpenter RL, Kenter ME,et al. Effect of epinephrine on central nervous system and cardiovascular system toxicity of bupivacaine in pigs. Anesthesiology 1989; 71: 711–7.
35. Coyle DE, Sperelakis N. Bupivacaine and lidocaine blockade of calcium-mediated slow action potentials in guinea pig ventricular muscle. J Pharmacol Exp Ther 1987; 242: 1001–5.
36. Reuter H. Calcium channel modulation by neurotransmitters, enzymes and drugs. Nature 1983; 301: 569–74.
© 2001 International Anesthesia Research Society
37. McCaslin PP, Butterworth J. Bupivacaine suppresses [Ca2+
]i oscillations in neonatal rat cardiomyocytes with increased extracellular K+
and is reversed with increased extracellular Mg2+
. Anesth Analg 2000; 91: 82–8.